Jeff P Sharman1, Steven E Coutre2, Richard R Furman3, Bruce D Cheson4, John M Pagel5, Peter Hillmen6, Jacqueline C Barrientos7, Andrew D Zelenetz8, Thomas J Kipps9, Ian W Flinn10, Paolo Ghia11, Herbert Eradat12, Thomas Ervin13, Nicole Lamanna14, Bertrand Coiffier15,16, Andrew R Pettitt17, Shuo Ma18, Eugen Tausch19, Paula Cramer20, Julie Huang21, Siddhartha Mitra21, Michael Hallek20, Susan M O'Brien22, Stephan Stilgenbauer19. 1. 1 Willamette Valley Cancer Institute and Research Center, US Oncology Research, Springfield, OR. 2. 2 Stanford School of Medicine, Stanford, CA. 3. 3 Weill Cornell Medical College, New York, NY. 4. 4 Georgetown University Hospital, Washington DC. 5. 5 Swedish Cancer Institute, Seattle, WA. 6. 6 St James's University Hospital, Leeds, United Kingdom. 7. 7 Zucher School of Medicine at Hofstra/Northwell, New Hyde Park, NY. 8. 8 Memorial Sloan Kettering Cancer Center, New York, NY. 9. 9 University of California, San Diego, Moores Cancer Center, La Jolla, CA. 10. 10 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN. 11. 11 Università Vita-Salute San Raffaele and Istituto Di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy. 12. 12 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA. 13. 13 Venice Regional Bayfront Health, Venice, FL. 14. 14 Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY. 15. 15 Centre Hospitalier Lyon-Sud, Pierre Benite, France. 16. † Deceased. 17. 16 University of Liverpool, Liverpool, United Kingdom. 18. 17 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. 19. 18 Ulm University, Ulm, Germany. 20. 19 University Hospital of Cologne, Cologne, Germany. 21. 20 Gilead Sciences, Foster City, CA. 22. 21 University of California, Irvine, Orange, CA.
Abstract
PURPOSE: A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-rituximab (IDELA/R) arm. Patients in either arm could then enroll in an extension study to receive IDELA monotherapy. Here, we report the long-term efficacy and safety data for IDELA-treated patients across the primary and extension studies. PATIENTS AND METHODS: Patients were randomly assigned to receive rituximab in combination with either IDELA 150 mg twice daily (IDELA/R; n = 110) or placebo (placebo/R; n = 110). Key end points were progression-free survival (PFS), overall response rate (ORR), overall survival (OS), and safety. RESULTS: The long-term efficacy and safety of treatment with IDELA was assessed in 110 patients who received at least one dose of IDELA in the primary study, 75 of whom enrolled in the extension study. The IDELA/R-to-IDELA group had a median PFS of 20.3 months (95% CI, 17.3 to 26.3 months) after a median follow-up time of 18 months (range, 0.3 to 67.6 months). The ORR was 85.5% (94 of 110 patients; n = 1 complete response). The median OS was 40.6 months (95% CI, 28.5 to 57.3 months) and 34.6 months (95% CI, 16.0 months to not reached) for patients randomly assigned to the IDELA/R and placebo/R groups, respectively. Prolonged exposure to IDELA increased the incidence of all-grade, grade 2, and grade 3 or greater diarrhea (46.4%, 17.3%, and 16.4%, respectively), all-grade and grade 3 or greater colitis (10.9% and 8.2%, respectively) and all-grade and grade 3 or greater pneumonitis (10.0% and 6.4%, respectively) but did not increase the incidence of elevated hepatic aminotransferases. CONCLUSION:IDELA improved PFS and OS compared with rituximab alone in patients with relapsed CLL. Long-term IDELA was effective and had an expected safety profile. No new IDELA-related adverse events were identified with longer exposure.
RCT Entities:
PURPOSE: A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-rituximab (IDELA/R) arm. Patients in either arm could then enroll in an extension study to receive IDELA monotherapy. Here, we report the long-term efficacy and safety data for IDELA-treated patients across the primary and extension studies. PATIENTS AND METHODS: Patients were randomly assigned to receive rituximab in combination with either IDELA 150 mg twice daily (IDELA/R; n = 110) or placebo (placebo/R; n = 110). Key end points were progression-free survival (PFS), overall response rate (ORR), overall survival (OS), and safety. RESULTS: The long-term efficacy and safety of treatment with IDELA was assessed in 110 patients who received at least one dose of IDELA in the primary study, 75 of whom enrolled in the extension study. The IDELA/R-to-IDELA group had a median PFS of 20.3 months (95% CI, 17.3 to 26.3 months) after a median follow-up time of 18 months (range, 0.3 to 67.6 months). The ORR was 85.5% (94 of 110 patients; n = 1 complete response). The median OS was 40.6 months (95% CI, 28.5 to 57.3 months) and 34.6 months (95% CI, 16.0 months to not reached) for patients randomly assigned to the IDELA/R and placebo/R groups, respectively. Prolonged exposure to IDELA increased the incidence of all-grade, grade 2, and grade 3 or greater diarrhea (46.4%, 17.3%, and 16.4%, respectively), all-grade and grade 3 or greater colitis (10.9% and 8.2%, respectively) and all-grade and grade 3 or greater pneumonitis (10.0% and 6.4%, respectively) but did not increase the incidence of elevated hepatic aminotransferases. CONCLUSION: IDELA improved PFS and OS compared with rituximab alone in patients with relapsed CLL. Long-term IDELA was effective and had an expected safety profile. No new IDELA-related adverse events were identified with longer exposure.
Authors: Lindsey E Roeker; Peter Dreger; Jennifer R Brown; Oscar B Lahoud; Toby A Eyre; Danielle M Brander; Alan Skarbnik; Catherine C Coombs; Haesook T Kim; Matthew Davids; Steven T Manchini; Gemlyn George; Nirav Shah; Timothy J Voorhees; Kim H Orchard; Harriet S Walter; Arvind K Arumainathan; Andrea Sitlinger; Jae H Park; Mark B Geyer; Andrew D Zelenetz; Craig S Sauter; Sergio A Giralt; Miguel-Angel Perales; Anthony R Mato Journal: Blood Adv Date: 2020-08-25
Authors: Diana G Wang; Dulce M Barrios; Victoria S Blinder; Jacqueline F Bromberg; Pamela R Drullinsky; Samuel A Funt; Komal L Jhaveri; Diana E Lake; Tomas Lyons; Shanu Modi; Pedram Razavi; Michelle Sidel; Tiffany A Traina; Linda T Vahdat; Mario E Lacouture Journal: Breast Cancer Res Treat Date: 2020-06-29 Impact factor: 4.872
Authors: Anthony R Mato; Nilanjan Ghosh; Stephen J Schuster; Nicole Lamanna; John M Pagel; Ian W Flinn; Jacqueline C Barrientos; Kanti R Rai; James A Reeves; Bruce D Cheson; Paul M Barr; Suman Kambhampati; Frederick Lansigan; Jeffrey J Pu; Alan P Skarbnik; Lindsey Roeker; Gustavo A Fonseca; Andrea Sitlinger; Issam S Hamadeh; Colleen Dorsey; Nicole LaRatta; Hanna Weissbrot; Eline T Luning Prak; Patricia Tsao; Dana Paskalis; Peter Sportelli; Hari P Miskin; Michael S Weiss; Jakub Svoboda; Danielle M Brander Journal: Blood Date: 2021-05-20 Impact factor: 22.113
Authors: Claudia Pérez-Carretero; Isabel González-Gascón-Y-Marín; Ana E Rodríguez-Vicente; Miguel Quijada-Álamo; José-Ángel Hernández-Rivas; María Hernández-Sánchez; Jesús María Hernández-Rivas Journal: Diagnostics (Basel) Date: 2021-05-10